You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live



▼  7th Inning 2 outs

Kala Pharmaceuticals: New $11.5m funding will help develop treatments for eye diseases

Kala Pharmaceuticals Inc. said Thursday that it has secured $11.5 million in Series A equity financing.

New and lead investor, Crown Venture Fund, LLC, the venture capital arm of the Crown family of Chicago, joined Kala’s existing investors, including Lux Capital Management, Polaris Venture Partners and Third Rock Ventures, the Waltham-based company said in a press release.

Continue reading below

Kala Pharmaceuticals is developing products that are capable of penetrating mucosal barriers for the treatment of major diseases that affect the eyes, lungs, gastrointestinal tract, and female reproductive system. The company is initially focusing on ophthalmic programs.

“Kala’s front of the eye drug delivery advantages and ability to topically deliver a wide variety of drugs to the back of the eye will transform the ophthalmology sector,” Richard Robb, a representative for Crown Venture Fund, said in a statement.

In a separate statement, Kala chief executive Guillaume Pfefer said, “This financing provides Kala with the resources to further deploy our technology as we focus our internal drug development efforts on innovative ophthalmic treatments while leveraging our platform to pursue collaborations for a range of other diseases where mucosal barriers have previously limited therapeutic efficacy.

One of Kala’s cofounders is Robert Langer of the Massachusetts Institute of Technology.

Chris Reidy can be reached at
Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of